Dr. John Houston serves as President and Chief Executive Officer at Arvinas. With over 30 years of experience, he served as the Senior Vice President of Specialty Discovery at Bristol Myers Squibb (BMS). He spent more than 18 years at BMS in roles of increasing responsibility and had accountability for all Discovery Biology disease teams as well as various Discovery technology departments. Dr. Houston was a member of the BMS R&D Executive Leadership team and chaired the Target Portfolio Committee, which had governance oversight in the discovery space. With his teams and research colleagues, he progressed over 200 compounds into early development, several of which advanced into late-stage clinical trials and toward commercialization.
Prior to joining Bristol Myers Squibb, he worked at Glaxo Wellcome Research and Development in the UK, where he served as head of the Lead Discovery Unit. Dr. Houston currently serves on the boards of directors of NextCure, Inc., Oerth Bio, Cybrexa Therapeutics and BioCT.
Dr. Houston obtained his B.Sc. degree in Medical Microbiology from Glasgow University and obtained his Ph.D. in Microbial Biochemistry from Heriot-Watt University, Edinburgh. He also completed his post-doctoral studies on an MRC grant at Glasgow University.